WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility

SHANGHAI, Sept. 20 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good Laboratory Practice (GLP) compliance from the Organization for Economic Cooperation and Development (OECD) for toxicology and mutagenicity studies conducted at the company's Suzhou facility.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

(Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO )

The OECD is an inter-governmental organization in which representatives of 29 industrialized countries in North America (including the United States), Europe, and the Pacific, as well as the European Commission, work together on issues of mutual concern. The OECD has developed Principles of Good Laboratory Practice to promote the quality and validity of test data used for determining the safety of chemicals and chemical products. Good Laboratory Practice is a quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported.

The certificate recognizes that our Suzhou facility is operating in compliance with OECD Principles of Good Laboratory Practice. Award of the certificate resulted from a one-week inspection conducted by the Belgian national GLP compliance monitoring authority. In addition to an extensive facility assessment, the inspection included an audit of two general toxicology studies and four genetic toxicology studies. The facility inspection evaluated key operational areas, including vivarium rooms, pharmacy, analytical chemistry, clinical pathology, histopathology, and central archive.

"This certificate from the OECD is an important acknowledgment that we now have the capability to offer our clients GLP toxicology studies that meet international GLP quality standards," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "With this award, WuXi moves a step closer to achieving its goal of offering our pharmaceutical and biotech clients a comprehensive, fully integrated platform of pharmaceutical R&D services."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Stephanie Liu (for the media)
     Tel:   +86-21-5046-4362
     Email: [email protected]

     Ronald Aldridge (for investors)
     Tel:   +1-201-585-2048
     Email: [email protected]

SOURCE WuXi PharmaTech

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED